GENESIS OF GASTROINTESTINAL TRACT LESIONS IN RHEUMATOLOGICAL PATIENTS.
Abstract
The pathogenesis of damage to the gastrointestinal tract in rheumatological patients at the onset of the disease, according to modern literature, has not been sufficiently studied, and the conclusions are also not clear. This article presents the results of studies of the state of the gastrointestinal tract in rheumatological patients at the onset of the disease and during treatment with basic drugs and NSAIDs. The study revealed clinical and functional changes in the gastrointestinal tract, an imbalance between protective factors and aggressive factors, and determined their role in the development of the pathological process in the digestive tube.
References
1. Nasonov EL, Alexandrova EH, Novikov AA. Autoimmune rheumatic diseases - immunological problems pathology and personalized therapy. Bulletin of the Russian Academy of Medical Sciences. 2015;70(2):169-82
2.Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015; 278:369-95. doi: 10.1111/joim.12395
3. American Autoimmune Related Diseases Association. Autoimmune Disease Statistics. Available from: https://www.aarda.org/news-information/statis-tics/#1488234345468-3bf2d325-1052.2017
4. Karateev AE, Nasonov EL, Ivashkin VT, etc. Rational use of non-steroidal anti-inflammatory drugs. Clinical recommendations. Scientific and practical rheumatology. 2018; 56(S1): 1-29
Распространенность ревматических
заболеваний вРоссии
Распространенность ревматических
заболеваний вРоссии
Галушко ЕА, Насонов ЕЛ.
5. Galushko E.A., Nasonov E.L. Prevalence of rheumatic diseases in Russia. Almanac of Clinical Medicine. 2018;46(1):32–9.
6. Nasonov EL, Lila AM, Galushko EA, Amirdzhanova VN. Strategy for the development of rheumatology: from scientific achievements to practical healthcare. Scientific and practical rheumatology. 2017;55(4):339-343.
7. Akulova A. I., Gaidukova I. Z., Aparkina A. V., Rebrov A. P. Damage to the gastrointestinal tract in rheumatic diseases lesion Experimental and clinical gastroenterology, issue 130, No. 6, 2016 -P.70 -74.
8. Maev I.V., Andreev D.N., Dicheva D.T., Zhilyaev E.V. New ideas about gastropathy associated with the use of non-steroidal anti-inflammatory drugs Consilium Medicum. 2017; 19 (8): 110 -115
9. Nasonov E.L., Ivashkin V.T., Yakhno N.N., Martynov A.I., Arutyunov G.P., Karateev A.E., Alekseeva L.I., Chichasova N.V., Evseev M.A., Kukushkin M.L., Lila A.M., Rebrov A.P., Novikova D.S., Kopenkin S.S., Abuzarova G.R., Skorobogatikh K.V., Lapina T. L.L., Popkova T.V. Draft National Clinical Guidelines (main provisions) of the Association of Rheumatologists of Russia, Russian Gastroenterological Association, Russian Society for the Study of Pain “Rational use of non-steroidal anti-inflammatory drugs” Russian Journal of Gastroenterology, Hepatology, Coloproctology 2017; 27(5):69-75
10. Morozova T. E., Rykova S. M., Chukina M. A. NSAID gastropathy in patients with combined pathology of the cardiovascular system and diseases of the joints and spine. Experimental and clinical gastroenterology. 2015, no. 6, 64-70.
11. Nasonova V. A. Rational pharmacotherapy of rheumatic diseases: A guide for practitioners / Ed. ed. V. A. Nasonova, E. L. Nasonova. - M.: Litterra, 2003. - 507 p.
12. Efficiency and safety of drug therapy in primary and secondary prevention of cardiovascular diseases. All-Russian Society of Cardiologists. Section of rational pharmacotherapy. 2011
13. Karateev A.E. Quantitative and qualitative assessment of the risk of complications when using non-steroidal anti-inflammatory drugs as the basis for developing recommendations for their control and prevention // Modern Rheumatology. - 2014. - No. 1. - P. 64-72.
14. Lazebnik L.B., Golovanova E.V., Alekseenko S.A. and others. Recommendations for the prevention and treatment of esophago-gastro-entero-colopathies induced by non-steroidal anti-inflammatory drugs (NSAIDs). Experimental and clinical gastroenterology. 2018; 151(3): 4 -18.
15. Pakhomova I.G., Knorring G.Yu. Features of the use of non-steroidal anti-inflammatory drugs in comorbid patients. How to minimize the risks of NSAID-induced gastrointestinal complications? Doctor.Ru. 2020; 19(7): 68–75.
16. Balukova E.V. NSAID-induced gastropathy: from understanding the mechanisms of development to developing strategies for prevention and treatment. RMJ 2017, 10, 697-702.
17. Alekperov R.T., Baranov A.A., Abaitova N.E. Associations of C-reactive protein levels with clinical manifestations in systemic scleroderma. Therapeutic archive, 2006, No. 6, pp. 30-35.
16. Ruchkina I.N., Parfenov A.I., Tsaregorodtseva T.M. Immunological aspects of the use of probiotics. // Gastroenterology of St. Petersburg, – 2007. – No. 1-2. – P.11-14.
18. Loginov A.S., Parfenov A.I. Intestinal diseases. Guides for doctors. M.: Medicine, 2000. – 632 p.
19. Sibirkina M.V., Marufkhanov Kh.M. Prerequisites for functional or organic disorders of the gastrointestinal tract in rheumatological patients treated with NSAIDs. International Journal of Education, Social Science & Humanities. Finland Academic Research Science Publishers 2023. Vol. 11.:363-376
